Cargando…
AML-337: Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy
Acute myeloid leukemia (AML) is an aggressive heterogeneous hematologic disease with high mortality in patients older than 60 years. Clinical studies have proven that combinations of FDA-approved Bcl-2 inhibitor, venetoclax and hypomethylating agents (HMA) are highly effective in elderly patients wi...
Autores principales: | Chang, Kyung Hee, Zhang, Weiguo, Basyal, Mahesh, Ostermann, Lauren, Fogler, William, Magnani, John, Andreeff, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833936/ http://dx.doi.org/10.1016/S2152-2650(20)30760-6 |
Ejemplares similares
-
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
por: Muz, Barbara, et al.
Publicado: (2019) -
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271
por: Natoni, A, et al.
Publicado: (2017) -
Use of GMI‐1271, an E‐selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis
por: Devata, Sumana, et al.
Publicado: (2020) -
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML
por: Jia, Yannan, et al.
Publicado: (2023) -
AML-343: Loss of H3K27 Methylation Identifies Poor Outcomes in Adult-Onset Acute Lymphoblastic and Myeloid Leukemia
por: Dijk, Anneke van, et al.
Publicado: (2020)